Δ133p53α Protects Human Astrocytes from Amyloid-Beta Induced Senescence and Neurotoxicity
Kyra UngerleideriD, Jessica A. BeckiD, Delphine LissaiD, Sebastien M. JoruiziD, Izumi HorikawaiD, Curtis C. HarrisiD
Abstract
Cellular senescence is an important contributor to aging and age-related diseases such as Alzheimers disease (AD). Senescent cells are characterized by a durable cell proliferation arrest and the acquisition of a proinflammatory senescence-associated secretory phenotype (SASP), which participates in the progression of neurodegenerative disorders. Clearance of senescent glial cells in an AD mouse model prevented cognitive decline suggesting pharmacological agents targeting cellular senescence might provide novel therapeutic approaches for AD. {Delta}133p53, a natural protein isoform of p53, was previously shown to be a negative regulator of cellular senescence in primary human astrocyte, with clinical implications from its diminished expression in brain tissues from AD patients. Here we show that treatment of proliferating human astrocytes with amyloid-beta oligomers (A{beta}), an endogenous pathogenic agent of AD, results in reduced expression of {Delta}133p53, as well as induces the cells to become senescent and express proinflammatory SASP cytokines such as IL-6, IL-1{beta} and TNF. Our data suggest that A{beta}-induced astrocyte cellular senescence is associated with accelerated DNA damage, and upregulation of full-length p53 and its senescence-inducing target gene p21WAF1. We also show that exogenously enhanced expression of {Delta}133p53 rescues human astrocytes from A{beta}-induced cellular senescence and SASP through both protection from DNA damage and dominantnegative inhibition of full-length p53, leading to inhibition of A{beta}-induced, astrocyte-mediated neurotoxicity. The results presented here demonstrate that {Delta}133p53 manipulation could modulate cellular senescence in the context of AD, possibly opening new therapeutic avenues. HIGHLIGHTSO_LIA{beta} diminishes the expression of the p53 isoform {Delta}133p53, and induces cellular senescence, SASP, and DNA damage in human astrocytes. C_LIO_LI{Delta}133p53 protects human astrocytes from A{beta}-induced DNA damage and cellular senescence. C_LIO_LI{Delta}133p53 prevents astrocyte-mediated neurotoxicity to neuro-progenitor cells. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 24
- FWCI
- 0.63
- Field percentile
- top 33%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Astrocyte senescence in an Alzheimer’s disease mouse model is mediated by TGF-β1 and results in neurotoxicity
Shoshik Amram, Tal Iram, … Dan Frenkel·bioRxiv·Jul 12, 2019
- DNA damage drives a unique, Alzheimer's disease-relevant senescent state in neurons
Jun‐Wei B. Hughes, Anja Sandholm, … Judith Campisi·bioRxiv·Apr 3, 2026
- Telomere-induced senescence increases aberrant intraneuronal amyloid-β accumulation by impairing autophagy in a mouse model of Alzheimer's disease
Núria Suelves, Shirine Saleki, … Pascal Kienlen‐Campard·Acta Neuropathologica CommunicationsPeer-reviewed·May 17, 2023
- A-beta-induced distress of astrocytes triggers Alzheimer disease pathology through non-canonical delta secretase activity
Vanessa Schmidt, Ewelina Ziemlińska, … Anna R. Malik·bioRxiv·Jan 30, 2025
- A 3D human iPSC-derived multi-cell type neurosphere system to model cellular responses to chronic amyloidosis
Stefan Wendt, Ada J. Lin, … Haakon B. Nygaard·Journal of NeuroinflammationPeer-reviewed·Apr 24, 2025
- Bisdemethoxycurcumin mitigates Alzheimer disease pathology through autophagy-mediated reduction of senescence and amyloid beta
Parul Khajuria, Dilpreet Kour, … Ajay Kumar·bioRxiv·May 19, 2025